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Regarding impact of epoetin
alfa on clinical end points in
patients with chronic renal
failure: A meta-analysis
To the Editor: We read the recent article by Jones
et al [1] with interest. This meta-analysis purports to show
that recombinant human erythropoietin (rHuEPO) ther-
apy increases hemoglobin levels and reduces hospital-
ization rates. Unfortunately, the design of this study has
several potential limitations that were not expressed in
the manuscript.
First, the inclusion criteria were so exclusive that sev-
eral relevant trials were not included, which may have
influenced the outcome of the meta-analysis. It is note-
worthy that these criteria excluded the three largest and
most recent randomized studies. An example of an ex-
cluded study that might have altered the pooled effect of
rHuEPO therapy is the work by Besarab et al [2].
Second (and more important), 11 of 16 trials included
were nonrandomized. Because nonrandomized studies
are more likely to exaggerate estimates of treatment ef-
fect [3, 4], and because inclusion of lower quality studies is
known to affect the results of meta-analyses [5], we urge
that the reader be circumspect of results driven by these
11 trials alone. Because the excluded trials tended to find
no benefit of rHuEPO with respect to hospitalization, we
wonder what the meta-analysis would have shown if all
available randomized trials were considered.
In addition to these considerations about study de-
sign, we disagree with the authors’ interpretation of the
data. The authors state that “strong evidence” shows
that rHuEPO reduces hospitalization rates, and by ex-
tension, healthcare costs. However, hospitalization costs
are determined primarily by the number of hospital days,
rather than by the total number of hospitalizations. While
Jones et al state that the length of stay was reduced
with rHuEPO therapy, its “benefit” was not statistically
significant.
Although erythropoietic therapy undoubtedly raises
hemoglobin levels and probably improves quality of life,
the available data do not convincingly indicate that it re-
duces hospitalization rates in people with kidney disease.
Rather, we view the information as weak and inconsis-
tent.
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Editor’s note: The study by Jones et al was sponsored
by RW Johnson Pharmaceutical Research and Develop-
ment (Raritan, NJ), a subsidiary of Johnson and John-
son, which operates companies that manufacture epoetin
alfa.
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The letter from Tonelli et al [1] concerning our work
reveals what we consider to be a number of misunder-
standings and inconsistencies, which we would like to
address.
The work is criticized as being too exclusive (i.e., omit-
ting Besarab et al [2]), and at the same time, too inclusive
in that it included studies other than randomized con-
trolled trials (RCTs). Besarab et al [2] is actually a study
of congestive heart failure patients on dialysis, and not
directly relevant to our focus on chronic renal failure pa-
tients. Within this population, we sought to include all
evidence available.
We must, however, strenuously reject the assertion
from the letter’s first paragraph “. . . potential limitations
that were not expressed in the manuscript.” The use of
non-RCTs, as well as the strengths and weaknesses of
the accumulated data, are all well documented in the
manuscript.
We agree the impact of research design is a criti-
cally important issue. However, perhaps it was not im-
mediately clear that Table 5 reanalyzes the data from
RCTs alone. In contrast to the assertion by Tonelli
et al, the estimates of effect from the RCT’s are simi-
lar to, or slightly larger than, those from all studies as a
whole.
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Tonelli et al disagree with our interpretation of the
hospitalization data. While hematocrit and quality of
life were the central focus of our work, we also believe
that the hospitalization rate data suggest a benefit with
epoetin alfa. We look forward to further research to cor-
roborate these findings.
Overall, we would not represent the results in our work
as anything but what they are, a synthesis of the available
evidence with all its strengths and weaknesses. We believe
the criticisms put forth by Tonelli et al stem largely from
a misunderstanding of our article.
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Mycophenolate mofetil in IgA
nephropathy
To the Editor: We wish to raise several issues regard-
ing the publication by Maes et al [1], reporting on the
effectiveness of mycophenolate mofetil (MMF) in IgA
nephropathy (IgAN): (1) A sample of 34 patients is too
little. We have started a randomized trial, ramipril versus
ramipril plus MMF in IgAN [2]: 57 patients per group are
required to maintain a power of 80% and a type error of
5%. For a dropout rate of 10%, a total sample size of
126 patients needs to be enrolled. In the placebo group,
2 patients (1 death, 1 adverse event) out of 13 patients
(15%), and in the MMF group, 8 patients [2 end-stage
renal disease (ESRD), 2 emigrated, 1 adverse event, 1
tuberculosis (TB), 2 gastrointestinal (GI) problems] out
of 21 patients (38%) reduced or stopped the treatment
before the end of the trial.
(2) Inclusion criteria. “Eligible patients were random-
ized (2:1; MMF:placebo).” In a randomized trial all pa-
tients should have the same probability of receiving one
or the other of the treatments being compared [3]. Renal
function for inclusion was taken at the time of diagnosis
(ie, 0 to 5 years back from randomization). Were patients
with glomerular filtration rate (GFR) <20 mL/min in-
cluded? Options for eligibility were also hypertension,
proteinuria, and histologic severity, alone or in combina-
tion. Were these risk factors evenly distributed between
groups?
(3) A wash-out period for patients assuming enalapril
was not performed, biasing proteinuria at entry.
(4) In a small patient sample, data distribution is not
usually normal and a nonparametric approach would
have been more appropriate.
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We agree that, from a statistical point of view, the study
is not powered to prove differences or equivalence be-
tween the two groups. Therefore, large multicenter trials
are warranted. Even a study of 126 patients is small to un-
equivocally prove superiority of mycophenolate mofetil
(MMF) treatment over standard renoprotective treat-
ment (including salt restriction, angiotensin II suppres-
sion) plus frequent follow-up (compliance). Using the
data from our study population, the number of patients
per group after dropout would have to be 83 to maintain
a power of 80% and an a-value of 0.05 [1, 2]. Because that
number could not be reached, a 2:1 randomization was
performed in order to maximize the number of patients
exposed to MMF. We clearly stated this in the abstract
and discussion section of the manuscript.
As stated, patients with GFR <20 mL/min were ex-
cluded, and risk factors did not differ significantly be-
tween groups alone or in combination.
